Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Elelgrupi | Pharma | 24.1% | 65th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Grasse Pharma Georgia | Pharma | — | no FY data | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
| Medimex | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 5 peers filed FY2024. Switch to FY2023 (3 of 5).
| Ratio — FY 2024 | Elelgrupi | Pip Company | Grasse Pharma Georgia | Sando Pharma | Medimex |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 53.4% | 8.0% | — | — | — |
| EBITDA Margin | 24.1% | -15.5% | — | — | — |
| EBITDAR | 424 | -188 | — | — | — |
| EBITDAR Margin | 27.8% | -14.7% | — | — | — |
| EBIT Margin | 24.1% | -15.6% | — | — | — |
| Net Profit Margin | 20.6% | -24.2% | — | — | — |
| Operating Expense % of Sales | 29.3% | 23.6% | — | — | — |
| Returns | |||||
| Return on Assets (ROA) | 15.7% | -9.2% | — | — | — |
| Return on Equity (ROE) | 23.1% | N/A | — | — | — |
| ROIC [EBIT / Invested Capital] | 30.9% | N/A | — | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | — | — | — |
| Debt-to-Equity | 0.00x | -0.00x | — | — | — |
| Debt-to-EBITDA | 0.00x | N/A | — | — | — |
| Equity-to-Assets | 68.3% | -47.2% | — | — | — |
| Net Debt | -169 | -3 | — | — | — |
| Cash & Equivalents | 169 | 3 | — | — | — |
| Total Debt | N/A | N/A | — | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.28x | 0.68x | — | — | — |
| Quick Ratio | 0.28x | 0.68x | — | — | — |
| Cash Ratio | 0.39x | 0.00x | — | — | — |
| Total Current Assets | 120 | 3,360 | — | — | — |
| Total Current Liabilities | 431 | 4,920 | — | — | — |
| Inventory | N/A | N/A | — | — | — |
| Trade Receivables | 796 | 2,662 | — | — | — |
| Trade Payables | 82 | 4,920 | — | — | — |
| Net Working Capital | -310 | -1,560 | — | — | — |
| Net Working Capital % of Revenue | -20.4% | -122.2% | — | — | — |
| Trade Working Capital | 714 | -2,258 | — | — | — |
| Trade Working Capital % of Revenue | 46.9% | -176.9% | — | — | — |
| Change in Trade Working Capital | N/A | N/A | — | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | — | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | — | — | — |
| Receivables Turnover | 1.92x | 0.48x | — | — | — |
| Days Sales Outstanding (DSO) | 190.6 | 761.2 | — | — | — |
| Payables Turnover | 8.70x | 0.24x | — | — | — |
| Days Payable Outstanding (DPO) | 41.9 | 1529.5 | — | — | — |
| Cash Conversion Cycle | 148.7 days | -768.3 days | — | — | — |
| Asset Turnover | 0.77x | 0.38x | — | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 1,639 | N/A | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | -38 | N/A | — | — | — |
| Cash Conversion (OCF / EBITDA) | 445.5% | N/A | — | — | — |
| Dividends Declared | N/A | N/A | — | — | — |
| Dividend Payout Ratio | N/A | N/A | — | — | — |